1-8 of 8
John D Davis
Close
Save search
Sort by
Journal Articles

Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Free
Oleg Milberg, Joannellyn Chiu, Anasuya Hazra, Sameer Upadhyay, Glenn S. Kroog, Karen Rodriguez Lorenc, John D. Davis, A. Thomas DiCioccio, Lutz O. Harnisch, Jason Chittenden
Journal: Blood
Blood (2024) 144 (Supplement 1): 7056.
https://doi.org/10.1182/blood-2024-200109
Published: 2024
Journal Articles

Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1

Free
Anasuya Hazra, Anita Boyapati, Ching-Ha Lai, Kate Knorr, Dhruti Chokshi, Glenn S. Kroog, Karen Rodriguez Lorenc, A. Thomas DiCioccio, John D. Davis
Journal: Blood
Blood (2024) 144 (Supplement 1): 3310.
https://doi.org/10.1182/blood-2024-200880
Published: 2024
Journal Articles

Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies

Free
Min Zhu, Daniela Conrado, Kamal Srinivasan, Jurriaan Brouwer-Visser, Hong Yan, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Lutz Harnisch, John D Davis
Journal: Blood
Blood (2023) 142 (Supplement 1): 1436.
https://doi.org/10.1182/blood-2023-180675
Published: 2023
Journal Articles

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Free
Masood Khaksar Toroghi, Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11930–11931.
https://doi.org/10.1182/blood-2022-158412
Published: 2022
Journal Articles

Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach

Free
Min Zhu, Michael Dodds, Srikanth R. Ambati, Hesham Mohamed, Jason Chittenden, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 8855–8856.
https://doi.org/10.1182/blood-2022-158416
Published: 2022
Journal Articles

Modeling and Simulation in Support of Odronextamab Subcutaneous Dose Selection for Adult Patients with Indolent or Aggressive Non-Hodgkin Lymphoma

Free
Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Masood Khaksar Toroghi, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 11579–11580.
https://doi.org/10.1182/blood-2022-158409
Published: 2022
Journal Articles

Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome

Free
Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Vladimir Jankovic, Fang Wang, Hong Yan, Jingxian Cai, Carolina Leite De Oliveira, Melanie Ufkin, John D. Davis, Aafia Chaudhry, Masood Khaksar Toroghi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11560–11561.
https://doi.org/10.1182/blood-2022-158415
Published: 2022
Journal Articles

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Free
Masood Khaksar Toroghi, Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, Hong Yan, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11912–11913.
https://doi.org/10.1182/blood-2022-158413
Published: 2022